Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
Description
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS) antibodies that exist in diverse individuals as public antibody clones. We rationally selected RBS antibodies resilient to mutations in emerging Omicron subvariants
